Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
Date:10/11/2011

CAMBRIDGE, Mass., Oct. 11, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, combined with paclitaxel (Taxol®) in the neoadjuvant setting of HER2-negative breast cancer patients.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

The Phase 2 study is designed to evaluate whether the combination of MM-121 with paclitaxel is more effective than treatment with paclitaxel alone when administered as part of a neoadjuvant treatment regimen in HER2-negative, locally advanced breast cancer patients. A total of 200 patients are expected to be enrolled in the study. Following treatment with MM-121 and paclitaxel, or paclitaxel alone, patients will receive standard treatment with doxorubicin and cyclophosphamide and monitored until surgical resection. Multiple sites in North America are currently expected to participate in this study. The first patient was enrolled at Texas Oncology - Memorial City.

Merrimack entered into an exclusive, global collaboration and licensing agreement with Sanofi for MM-121 in 2009.

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by early 2012.

Contact: Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043,
kgallagher@merrimackpharma.com
Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424,
betsy@raymondstevenson.com


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
2. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
3. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
4. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
5. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
6. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
7. Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer
8. Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
9. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
10. Inovio Pharmaceuticals Synthetic Vaccine for Cancer Recognized as Most Promising Research at Global Vaccine Congress
11. OncoMed Pharmaceuticals Names Dr. Jakob Dupont VP Clinical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... -- NetworkNewsWire Editorial Coverage  ... There are a number of ... but economic arguments also favor its legalization. The benefits include ... However, to legalize and regulate marijuana requires an ecosystem of ... ( SING Profile ), American Cannabis Company (OTC: AMMJ), Kush ...
(Date:3/29/2017)... - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical ... ended December 31, 2016 after market close on ... released later than the previous fiscal year,s results ... and balances of Apicore from the acquisition date ... date meets TSX Venture Exchange listed company requirements. ...
(Date:3/28/2017)... -- The global emerging cancer diagnostics market is expected ... to 2023 and reach a figure of $6.34 billion ... chronic disease and is affecting a huge population. Many ... report is focused on emerging cancer diagnostics market specifically ... due to factors such as: increasing number of cancer ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... The Wall Centre Dental ... new patients from Burnaby, BC. Patients in need of experienced orthodontics, laser dentistry, ... see the esteemed team at Wall Centre Dental. Drs. Parviz Roshan, Siamak Tehrani, ...
(Date:3/29/2017)... OK (PRWEB) , ... March 29, 2017 , ... ... now receive FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with ... straighten teeth efficiently, compared to traditional orthodontic treatment. Depending on each patient’s case, ...
(Date:3/29/2017)... ARBOR, Mich. (PRWEB) , ... ... ... Retailer and Manufacturer Alliance (GRMA) is growing as it continues developing an ... dietary supplement industry. The organization, which plans to publish the first ANSI-approved ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices has recently updated its Visio ... shapes for free and download shapes and stencils from http://www.VisioStencils.com. , ...
(Date:3/29/2017)... PITTSBURGH, PA (PRWEB) , ... March 29, 2017 ... ... and hassles associated with wearing oral braces. "The rubber bands used in conjunction ... he said, "so I decided to design a way to prevent this problem." ...
Breaking Medicine News(10 mins):